BiotechTube

Sandostatine LP

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Congenital Hyperinsulinism

Conditions

Congenital Hyperinsulinism

Trial Timeline

May 1, 2009 → Jun 1, 2011

NCT ID
NCT00987168

About Sandostatine LP

Sandostatine LP is a phase 2 stage product being developed by Novartis for Congenital Hyperinsulinism. The current trial status is completed. This product is registered under clinical trial identifier NCT00987168. Target conditions include Congenital Hyperinsulinism.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00987168Phase 2Completed

Competing Products

20 competing products in Congenital Hyperinsulinism

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
15
Tideglusib + PlaceboAMO PharmaPhase 2/3
57
TideglusibAMO PharmaPhase 2/3
57
EDIT-101Editas MedicinePhase 1/2
33
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
TildacerfontSpruce BiosciencesPhase 2
44
KW-3357Kyowa KirinPhase 1
33
Pasireotide 0.6Mg Solution for Injection + Saline SolutionNovartisPhase 2
52
mycophenolate mofetilRochePhase 1
33
turoctocog alfa + turoctocog alfaNovo NordiskPhase 3
76
catridecacog + recombinant factor XIIINovo NordiskPhase 1
32
activated recombinant human factor VIINovo NordiskPhase 2
51
turoctocog alfa pegolNovo NordiskPhase 3
76
recombinant factor XIIINovo NordiskPre-clinical
22
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long actingNovo NordiskPhase 1
32
Advate® + turoctocog alfaNovo NordiskPhase 1
32
nonacog beta pegolNovo NordiskPhase 3
76

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85